The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease

(2019) Oliver Preische et al.   NATURE MEDICINE

Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report

(2019) Peter T Nelson et al.   BRAIN

Determining clinically meaningful decline in preclinical Alzheimer disease

(2019) Philip S. Insel et al.   NEUROLOGY

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status

(2019) Sebastian Palmqvist et al.   JAMA Neurology

Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays

(2019) Kaj Blennow et al.   Scientific Reports

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts

(2018) Rachel F. Buckley et al.   Alzheimers & Dementia

Validation study of the Alzheimer’s disease assessment scale–cognitive subscale (ADAS-Cog) for the Portuguese patients with mild cognitive impairment and Alzheimer’s disease

(2018) Joana Nogueira et al.   CLINICAL NEUROPSYCHOLOGIST

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease

(2018) Karra D. Harrington et al.   NEUROBIOLOGY OF AGING

Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data

(2018) Isabelle Bos et al.   Frontiers in Aging Neuroscience

Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia

(2018) Willemijn J. Jansen et al.   JAMA Psychiatry

Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders

(2018) Bob Olsson et al.   JAMA Neurology

Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons

(2017) Michael C. Donohue et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Blood-based NfL

(2017) Oskar Hansson et al.   NEUROLOGY

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity

(2017) Sebastian Palmqvist et al.   Nature Communications

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

(2016) Bruno Dubois et al.   Alzheimers & Dementia

Cognitive Aging: What Every Geriatric Psychiatrist Should Know

(2016) Dan G. Blazer et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

Using Robust Normative Data to Investigate the Neuropsychology of Cognitive Aging

(2016) Karra D. Harrington et al.   ARCHIVES OF CLINICAL NEUROPSYCHOLOGY

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography

(2016) Sebastian Palmqvist et al.   BRAIN

Certified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning

(2016) Jason Hassenstab et al.   NEUROBIOLOGY OF AGING

Neurofilament light chain: a biomarker for genetic frontotemporal dementia

(2016) Lieke H. Meeter et al.   Annals of Clinical and Translational Neurology

Conventional and robust norming in identifying preclinical dementia

(2015) Ellen Grober et al.   JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY

Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis

(2015) Wataru Sako et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

mixtools: AnRPackage for Analyzing Finite Mixture Models

(2015) Tatiana Benaglia et al.   Journal of Statistical Software

Multiple Brain Markers are Linked to Age-Related Variation in Cognition

(2014) Trey Hedden et al.   CEREBRAL CORTEX

Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42

(2014) Sebastian Palmqvist et al.   JAMA Neurology

TDP-43 Pathology, Cognitive Decline, and Dementia in Old Age

(2013) Robert S. Wilson et al.   JAMA Neurology

Effects of age and β-amyloid on cognitive changes in normal elderly people

(2012) Hwamee Oh et al.   NEUROBIOLOGY OF AGING

Selective review of cognitive aging

(2010) TIMOTHY A. SALTHOUSE   JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology

Neurodegenerative basis of age-related cognitive decline

(2010) R. S. Wilson et al.   NEUROLOGY

Quantification of Five Neuropsychological Approaches to Defining Mild Cognitive Impairment

(2009) Amy J. Jak et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

Robust norms for selected neuropsychological tests in older adults

(2008) R HOLTZER et al.   ARCHIVES OF CLINICAL NEUROPSYCHOLOGY

Robust and conventional neuropsychological norms: Diagnosis and prediction of age-related cognitive decline.

(2008) Susan De Santi et al.   NEUROPSYCHOLOGY